Last reviewed · How we verify

Placebo matched to fenebrutinib — Competitive Intelligence Brief

Placebo matched to fenebrutinib (Placebo matched to fenebrutinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Placebo (matched to BTK inhibitor). Area: Immunology.

phase 3 Placebo (matched to BTK inhibitor) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matched to fenebrutinib (Placebo matched to fenebrutinib) — Hoffmann-La Roche. This is a placebo control arm matched to fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell and myeloid cell activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo matched to fenebrutinib TARGET Placebo matched to fenebrutinib Hoffmann-La Roche phase 3 Placebo (matched to BTK inhibitor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Placebo (matched to BTK inhibitor) class)

  1. Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matched to fenebrutinib — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matched-to-fenebrutinib. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: